Subsequent Events

6 Months Ended

Mar. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

17. Subsequent Event

On April 30, 2022, the Company acquired substantially all of the assets of EUPROTEIN Inc. of North Brunswick, New Jersey (“EUPROTEIN”) for $4,250 in cash, of which $3,750 was paid at closing, with the remainder held back for final closing adjustments. EUPROTEIN offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. The acquired assets of EUPROTEIN will be part of Meridian’s Life Science segment and are expected to help the Company accelerate its pipeline of new immunological reagents, while expanding recombinant capabilities.